Axsome Therapeutics Valuation
Is 0HKF undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0HKF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0HKF ($98.01) is trading below our estimate of fair value ($1320.65)
Significantly Below Fair Value: 0HKF is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0HKF?
Key metric: As 0HKF is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0HKF's PS Ratio? | |
|---|---|
| PS Ratio | 14x |
| Sales | US$338.46m |
| Market Cap | US$4.73b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 13.6x |
| Enterprise Value/EBITDA | -18.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0HKF's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.4x | ||
HCM HUTCHMED (China) | 5x | 18.0% | UK£2.4b |
DPH Dechra Pharmaceuticals | 5.8x | 7.9% | UK£4.4b |
HIK Hikma Pharmaceuticals | 1.8x | 4.4% | UK£4.4b |
INDV Indivior | 1.2x | 5.5% | UK£1.1b |
0HKF Axsome Therapeutics | 14x | 38.7% | US$4.7b |
Price-To-Sales vs Peers: 0HKF is expensive based on its Price-To-Sales Ratio (14x) compared to the peer average (3.4x).
Price to Sales Ratio vs Industry
How does 0HKF's PS Ratio compare vs other companies in the GB Pharmaceuticals Industry?
| 1 Company | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
EAH ECO Animal Health Group | 0.5x | 5.9% | US$54.43m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 0HKF is expensive based on its Price-To-Sales Ratio (14x) compared to the European Pharmaceuticals industry average (2.9x).
Price to Sales Ratio vs Fair Ratio
What is 0HKF's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 14x |
| Fair PS Ratio | 15.2x |
Price-To-Sales vs Fair Ratio: 0HKF is good value based on its Price-To-Sales Ratio (14x) compared to the estimated Fair Price-To-Sales Ratio (15.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$98.01 | US$129.41 +32.0% | 16.2% | US$180.00 | US$105.00 | n/a | 17 |
| Nov ’25 | US$88.86 | US$125.29 +41.0% | 18.2% | US$180.00 | US$100.00 | n/a | 17 |
| Oct ’25 | US$89.60 | US$125.24 +39.8% | 18.2% | US$180.00 | US$100.00 | n/a | 17 |
| Sep ’25 | US$88.85 | US$124.31 +39.9% | 18.6% | US$180.00 | US$100.00 | n/a | 16 |
| Aug ’25 | US$85.77 | US$124.06 +44.6% | 20.0% | US$190.00 | US$95.00 | n/a | 17 |
| Jul ’25 | US$81.09 | US$123.75 +52.6% | 20.5% | US$190.00 | US$97.00 | n/a | 16 |
| Jun ’25 | US$72.96 | US$123.56 +69.4% | 20.5% | US$190.00 | US$97.00 | n/a | 16 |
| May ’25 | US$74.36 | US$122.69 +65.0% | 21.3% | US$190.00 | US$93.00 | n/a | 16 |
| Apr ’25 | US$79.48 | US$121.19 +52.5% | 22.5% | US$190.00 | US$90.00 | n/a | 16 |
| Mar ’25 | US$82.20 | US$120.53 +46.6% | 22.1% | US$180.00 | US$90.00 | n/a | 15 |
| Feb ’25 | US$93.80 | US$120.13 +28.1% | 23.1% | US$180.00 | US$90.00 | n/a | 14 |
| Jan ’25 | US$79.36 | US$114.92 +44.8% | 26.3% | US$180.00 | US$80.00 | n/a | 13 |
| Dec ’24 | US$67.86 | US$114.08 +68.1% | 27.4% | US$180.00 | US$80.00 | n/a | 12 |
| Nov ’24 | US$63.21 | US$115.90 +83.3% | 26.0% | US$180.00 | US$84.00 | US$88.86 | 12 |
| Oct ’24 | US$69.71 | US$116.59 +67.2% | 25.7% | US$180.00 | US$84.00 | US$89.60 | 12 |
| Sep ’24 | US$79.96 | US$116.34 +45.5% | 26.0% | US$180.00 | US$81.00 | US$88.85 | 12 |
| Aug ’24 | US$77.65 | US$112.96 +45.5% | 32.4% | US$190.00 | US$59.00 | US$85.77 | 12 |
| Jul ’24 | US$73.09 | US$113.29 +55.0% | 34.2% | US$200.00 | US$57.00 | US$81.09 | 12 |
| Jun ’24 | US$73.85 | US$111.50 +51.0% | 33.8% | US$200.00 | US$57.00 | US$72.96 | 13 |
| May ’24 | US$70.60 | US$107.75 +52.6% | 36.7% | US$200.00 | US$52.00 | US$74.36 | 13 |
| Apr ’24 | US$61.64 | US$106.61 +72.9% | 33.5% | US$200.00 | US$52.00 | US$79.48 | 16 |
| Mar ’24 | US$67.45 | US$107.54 +59.4% | 34.5% | US$210.00 | US$52.00 | US$82.20 | 16 |
| Feb ’24 | US$75.67 | US$109.36 +44.5% | 33.8% | US$210.00 | US$52.00 | US$93.80 | 16 |
| Jan ’24 | US$75.09 | US$109.35 +45.6% | 34.8% | US$210.00 | US$52.00 | US$79.36 | 15 |
| Dec ’23 | US$70.74 | US$110.08 +55.6% | 35.6% | US$210.00 | US$52.00 | US$67.86 | 14 |
| Nov ’23 | US$48.62 | US$99.98 +105.6% | 43.5% | US$210.00 | US$35.00 | US$63.21 | 15 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Formycon
€848.4m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€48.50
7D
4.3%
1Y
-21.3%
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
0ILL
€63.05
7D
1.3%
1Y
13.6%
Regeneron Pharmaceuticals
US$79.4b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$745.13
7D
-2.1%
1Y
-6.5%